Search results
Showing 7531 to 7545 of 7785 results
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Discontinued [GID-TA10897]
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development [GID-TA10899] Expected publication date: TBC
In development [GID-MT538] Expected publication date: TBC
In development [GID-TA11251] Expected publication date: TBC
This evidence summary has been withdrawn because the product is no longer available in the UK.
This guidance has been updated and replaced by NICE technology appraisal guidance 1045.
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
We have also recommended osimertinib for routine use on the NHS today.
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.